Abstract
Circulating miRNAs in small vesicles known as exosomes within blood have been emerging as a new research hotspot in the field of psychiatric disorders. The aim of this work was to characterize the changes in exosomal microRNA profiles, both short-term and long-term, during substance withdrawal using a cross-sectional study design. Using weighted gene co-expression network analysis, a series of known, conserved, and novel exosomal microRNAs were identified as being associated with withdrawal stage and key neurotransmitters GABA, choline, and serotonin. Bioinformatics analyses established that the differences in the miRNA profile target signaling pathways are associated with developmental and intellectual abnormalities. Notably, a set of dysregulated microRNA signatures including hsa-mia-451a and hsa-mir-21a resulted in an AUC of 0.966 and 0.861, respectively, for predicting patients with substance use disorders. Furthermore, hsa-miR-744a-5p was positively correlated with serotonin, and its important role in maintaining neuronal development and function was revealed using an in vitro human induced pluripotent stem cells derived neuronal model. Taken together, these data suggest that the microRNA content of circulating exosomes represent a biomolecular “fingerprint” of the progression of substance withdrawal and may uncover the putative mechanism of how these exosomal microRNAs contribute to central nervous system development and function.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
All patients were outpatients and signed the informed consent form. The study was approved by the ethical committee (2018-L-42).
Funding Statement
Foremost, we would like to thank Yongjin Zhang and Limei Cao for their expert technique assistance. This work was supported by grants from the National Natural Science Foundation of China (Grant No. 3171101074, 81860100, 31860306, and 81870458), Science and Technology Department of Yunnan Province (Grant No. 2018DH006, 2018NS0086, 202001AV070010), Yunnan Province Clinical Research Center (2019ZF012), and Yunling Scholar (Grant No. YLXL20170002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent for participation was provided by all individuals. The study was approved by the First Affiliated Hospital of Kunming Medical University Ethics Committee (2018-L-42).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: The authors declare that there are no conflicts of interest.
Data Availability
The clinical data of the patients used to support the findings of this study are included within the article. The original sequencing data of the microRNA used to support the findings of this study are available at PRJNA667326 of NCBI Sequence Read Archive (SRA).